Abstract: The objective of this study was to compare the demographic and vascular characteristics and APOE genotypes of a dysexecutive subgroup of Alzheimer disease (AD) with an amnestic subgroup of AD early in the disease course. A total of 2224 participants from the National Alzheimer's Coordinating Center database who carried a diagnosis of mild cognitive impairment (n = 1188) or mild AD (clinical dementia rating r1) (n = 1036) were included in this study. A subset of the mild cognitive impairment (n = 61) and mild AD (n = 79) participants underwent an autopsy. A dysexecutive subgroup (n = 587) was defined as having executive performance >1 SD worse than memory performance, and an amnestic subgroup (n = 549) was defined conversely. Among the autopsy subset, the odds of an AD pathologic diagnosis were compared in the 2 subgroups. The demographics, APOEe4 status, and vascular risk factors were compared in the 2 subgroups. Among the autopsy subset, the odds of having an AD pathologic diagnosis did not differ between the dysexecutive and amnestic subgroups. Under an additive model, participants in the dysexecutive subgroup possessed the APOEe4 allele less frequently compared with those in the amnestic subgroup. The dysexecutive subgroup had a history of hypertension less frequently compared with the amnestic subgroup. These distinct characteristics add to accumulating evidence that a dysexecutive subgroup of AD may have a unique underlying pathophysiology.
A lthough episodic memory loss is a classic early symptom of Alzheimer disease (AD), 1 the presentation of AD can be quite heterogenous. Examples include primary progressive aphasia, posterior cortical atrophy/visual variant, and a dysexecutive variant. 2, 3 Executive dysfunction refers to deficits in "planning, judgment, reasoning, problem solving, organization, attention, abstraction, and mental flexibility." 4 A subset of mild AD patients [clinical dementia rating (CDR) 5 of 0.5 or 1] has been described with substantial executive dysfunction in addition to deficits in memory. 2 Limited data exist regarding the demographic characteristics of AD patients with predominant executive dysfunction compared with AD patients with predominant memory dysfunction. A study of mild cognitive impairment (MCI) and mild AD (CDR=0.5) participants suggested that the dysexecutive and amnestic subgroups do not differ in sex, age, or education. 6 In contrast, another study revealed that AD patients (not restricted by CDR) with predominant executive dysfunction presented at a younger age and were disproportionately male. 7 Neither study evaluated ethnicity.
Significant biological differences have been noted between AD patients with predominant executive dysfunction compared with typical AD. One study found disproportionate amyloid plaque burden, 8 whereas another found disproportionate amyloid plaque and neurofibrillary tangle burden in the frontal lobes as compared with the typical distribution of pathology in AD. 9 Structural and functional imaging studies suggest that MCI and AD patients with predominant executive dysfunction have greater frontoparietal cortical thinning and hypometabolism compared with either controls or MCI and AD patients with predominant memory deficits. 6, [10] [11] [12] Assorted data exist regarding the frequency of the APOEe4 allele in the dysexecutive subgroup of MCI and AD. Two studies showed that the APOEe4 allele occurred significantly less frequently in MCI and AD patients with predominant executive dysfunction than in MCI and AD patients with predominant memory dysfunction. 6, 7 In another study, the APOEe4 allele occurred significantly more frequently in multidomain (dysexecutive and amnestic) MCI patients than in pure amnestic MCI (aMCI) patients. 13 Vascular risk factors may also contribute to executive dysfunction with or without AD. In normal aging, diabetes and hypertension have been associated with executive dysfunction. 14, 15 In AD, an increase in the number of vascular comorbidities has been associated with greater impairments in verbal reasoning and set shifting. 16, 17 Here, we compare the demographic and clinical characteristics and APOE genotypes of a dysexecutive subgroup of AD with an amnestic subgroup of AD early in the disease course. We hypothesize that the ethnic group, APOE genotype, and vascular risk factors will differ in the dysexecutive subgroup compared with that of the amnestic subgroup.
METHODS
The National Alzheimer's Coordinating Center (NACC) developed and maintains a large relational database of standardized clinical research data collected from the 29 NIA-funded Alzheimer disease centers (ADCs) nationwide. The study was approved by an institutional review board at each institution. The current study is a secondary analysis of data previously collected. Recruitment, participant evaluation, and diagnostic criteria for dementia, probable AD, and MCI are detailed elsewhere. 18 Each participant with MCI was further classified as having memory impairment (aMCI) or not having memory impairment (nonamnestic MCI). Each participant with aMCI was further classified into single domain (memory impairment only) or multiple domain (attention/processing speed, executive function, language, or visuospatial function). Because we were interested in the early presentation of AD, we restricted our sample to participants who met criteria for probable mild AD (CDRr1) or for single-domain or multiple-domain aMCI (who are more likely to progress to AD compared with nonamnestic MCI 19 ).
Race (white, African American, American Indian or Alaska native, Pacific Islander, Asian, or other) and presence of Hispanic/Latino ethnicity were ascertained by selfreport using 2 separate questions. All references to African Americans and whites imply non-Hispanic African Americans and non-Hispanic whites. Years of education was ascertained by self-report.
Stroke was defined according to the World Health Organization criteria, on the basis of self-report and supplemented by a neurological examination. History of diabetes, hypertension, hyperlipidemia, and myocardial infarction (MI) were ascertained by self-report at the first visit. A vascular risk score was assigned to each participant on the basis of the number of vascular risk factors (0 to 5).
All participants underwent the ADCs Uniform Data Set (UDS) neuropsychological battery. The tests include Digit Span Forward, Digit Span Backward, Digit Symbol, Trail Making Test (TMT) part A, TMT part B, Logical Memory Test story A (LMTA) immediate recall, LMTA delayed recall, Animal List Generation, Vegetable List Generation, and the Boston Naming Test. 20 The neuropsychological data were used from the first visit during which the diagnosis of MCI or AD was made.
An APOE genotype was determined for each participant and classified as having no APOEe4 alleles, 1 APOEe4 allele, or 2 APOEe4 alleles.
A total of 2224 (31%) of the 7126 eligible participants were included in this study. Inclusion criteria are illustrated in the flow chart in Figure 1 . Participants were excluded if they had incomplete neuropsychological testing, lacked APOE genotyping, or had incomplete vascular risk factor data. Included and excluded participants did not differ in sex or age. Compared with the included participants, the excluded participants were less educated by 0.4 years (P < 0.001), were disproportionately African American [odds ratio (OR) = 1.42, P < 0.001], and were disproportionately demented (OR = 1.24, P < 0.001).
Of the 2224 included participants, 140 underwent an autopsy. Compared with the nonautopsy subset, the autopsy subset was 6.7 years older (P < 0.001), had 0.6 more years of education (P = 0.017), was less likely to be African American (OR = 0.13, P = 0.004), and was less likely to be female (OR = 0.67, P = 0.022). Each autopsy participant was given a primary pathologic diagnosis. If AD pathology was present and considered by the pathologist to be the primary diagnosis, but did not meet the Reagan criteria, 21 the participant was still considered to have pathologic AD in our study.
Controls were diagnosed as normal at each annual NACC evaluation (n = 6385, first visit mean age = 71.3). Using neuropsychological data from their first visit, a mean and an SD were calculated for each test in the UDS. These were used to calculate the Z scores on each test for each participant with cognitive deficits. A global cognitive score was calculated for each participant by averaging the Z score on each of the UDS neuropsychological tests.
Classification of the "dysexecutive" and "amnestic" subgroups was made according to methods used by Dickerson and Wolk 6 in the AD Neuroimaging Initiative (ADNI) with modification due to test availability. The LMTA and the TMT were used to evaluate memory and executive function, respectively. This method was chosen because it uses neuropsychological tests (or variations on them) that are widely used so it can be easily replicated. The method has been shown to differentiate patients into subgroups who demonstrate consistent generalizable deficits in their respective cognitive domains on multiple neuropsychological tests. 6 In the LMTA, delayed recall was subtracted from immediate recall to account for learning ability. This value was termed the memory score. In the TMT, TMT A was subtracted from TMT B to account for attention. This value was termed the executive score. Even though all the participants needed to have cognitive impairment to be included in the study, they could have either positive or negative memory and executive scores because each of these scores was obtained by taking the difference between 2 neuropsychological tests. A mean and SD for the executive and memory scores were calculated. These were used to calculate the Z scores for each participant. Participants were considered members of the dysexecutive subgroup if their executive performance was Z1 SD below their memory performance. Participants were considered members of the amnestic subgroup if their memory performance was Z1 SD below their executive performance.
To determine whether the dysexecutive and amnestic subgroups also differed in other aspects of cognition, we calculated several composite scores on the basis of a recent factor analysis of the NACC cognitive battery in normal controls, MCI, and dementia. 22 Specifically, we calculated scores for each of the 4 identified neuropsychological factors by averaging the Z scores for each participant on the tests that make up the factor. The executive factor consisted of TMT A, TMT B, and Digit Symbol. The memory factor consisted of LMTA immediate recall and LMTA delayed recall. The language factor consisted of Boston Naming Test, Animal List Generation, and Vegetable List Generation. The attention factor consisted of Digit Span Forward and Digit Span Backward.
After controlling for variables that differed between the 2 subgroups (ie, age, education, ethnicity, APOEe4, and global cognition as demonstrated in the results section), the AD dysexecutive subgroup performed worse than the AD amnestic subgroup on the executive factor (P < 0.001), but performed better than the AD amnestic subgroup on the memory factor (P < 0.001) and the language factor (P < 0.001). They did not differ on the attention factor. After controlling for covariates, the MCI dysexecutive subgroup performed worse than the MCI amnestic subgroup on the executive factor (P < 0.001), but performed better than the AD amnestic subgroup on the memory factor (P < 0.001). They did not differ on the attention or language factors.
Statistical Analyses
All analyses were carried out in the entire sample and separately in MCI and AD participants. Among the pathologic subset, a w 2 test was used to compare the odds of an AD pathologic diagnosis in the dysexecutive subgroup, the amnestic subgroup, and those in neither subgroup. 
RESULTS
Among the 1188 participants with MCI, 294 met criteria for the dysexecutive subgroup, 283 met criteria for the amnestic subgroup, and 611 met criteria for neither subgroup. Among the 1036 patients with mild AD, 293 met criteria for the dysexecutive subgroup, 266 met criteria for the amnestic subgroup, and 477 met criteria for neither subgroup. The participants' demographic, clinical, and genetic characteristics are given in Table 1 .
In the AD dysexecutive subgroup, the mean executive score was À 1.04 ± 0.5, whereas in the AD amnestic subgroup, the mean executive score was + 0.99 ± 0.5. In the MCI dysexecutive subgroup, the mean executive score was À1.21 ± 0.9, whereas in the MCI amnestic subgroup, the mean executive score was + 0.68 ± 0.4. In the AD dysexecutive subgroup, the mean memory score was + 0.76 ± 0.8, whereas in the AD amnestic subgroup, the mean memory score was À0.99 ± 0.8. In the MCI dysexecutive subgroup, the mean memory score was + 0.70 ± 0.7, whereas in the MCI amnestic subgroup, the mean memory score was À1.17 ± 0.8. Although all the participants were required to have memory impairment for inclusion in the current study, an independent sample t test revealed that memory was significantly worse in the amnestic subgroup compared with the dysexecutive subgroup (P < 0.001).
Comparing Pathologic Diagnosis
Among the 61 autopsy cases with MCI, 22 met criteria for the dysexecutive subgroup and 11 met criteria for the amnestic subgroup. Among the 79 autopsy cases with mild AD, 26 met criteria for the dysexecutive subgroup and 15 met criteria for the amnestic subgroup. Both in MCI and mild AD, the 2 subgroups (and those in neither subgroup) did not differ in odds of having a pathologic diagnosis of AD (Table 2) . We also examined the rate of pathologic AD at autopsy in MCI participants that were excluded from the current study because they were defined as nonamnestic. Individuals with nonamnestic MCI (36.3%) trended lower compared with a subset of the amnestic single-domain MCI participants (60.9%).
Comparing Demographic Characteristics
Sex did not differ between the dysexecutive and amnestic subgroups in either MCI or mild AD. However, when stratified by diagnostic group across MCI and mild AD, other demographics of the cognitive subgroups differed substantially. After controlling for covariates, the MCI dysexecutive subgroup was older, had fewer years of education, and was more likely to identify as African American compared with the amnestic subgroup. After controlling for covariates, the AD dysexecutive subgroup was younger than the amnestic subgroup but did not differ in years of education or ethnicity (Table 3 ).
Comparing APOEe4 Status
Under an additive genetic model, after controlling for covariates, participants in the dysexecutive subgroup had 
There was no association between phenotype and AD pathologic diagnosis in MCI (P = 0.94) or mild AD (P = 0.21). AD indicates Alzheimer disease; MCI, mild cognitive impairment. (Table 4 ). The APOEe4 allele frequencies in whites (0.320) and African Americans (0.322) were quite similar in the NACC cohort. Because the APOEe4-AD association is weaker among African Americans than among whites, 24 and because there was a higher proportion of African American participants in the dysexecutive MCI subgroup as compared with the amnestic subgroup, we repeated the above analysis stratified by ethnicity. In African Americans, under an additive genetic model, after controlling for covariates, there was no difference in the odds of the APOEe4 allele. In whites, under an additive genetic model, after controlling for covariates, participants in the dysexecutive subgroup had smaller odds of possessing the APOEe4 allele compared with the participants in the amnestic subgroup (Table 5 ).
Comparing Vascular Risk Factors
After controlling for covariates, the dysexecutive and amnestic subgroups did not differ in odds of history of diabetes, stroke, hyperlipidemia, or MI. However, participants in the dysexecutive subgroup had smaller odds of having a history of hypertension compared with the participants in the amnestic subgroup (OR = 0.73, P = 0.040). Because of the possibility of additivity among vascular risk factors, we calculated a vascular score ranging from 1 to 5 on the basis of the number of vascular risk factors. After controlling for covariates, the vascular risk score did not differ in the 2 subgroups (Table 6 ).
DISCUSSION
Although episodic memory deficits are a classic early symptom of AD, the cognitive presentation of AD can be quite heterogenous. In this study, we explored the demographic, genetic, and the vascular characteristics of a dysexecutive subgroup of AD early in the disease course and compared these characteristics with an amnestic subgroup of AD. Participants were included in the analyses if they had single-domain aMCI, multiple-domain aMCI, or mild AD (CDRr1). Although it may have been informative to include those with nonamnestic executive MCI, we restricted our analyses to aMCI participants to increase our confidence that these individuals would progress to AD rather than a non-AD dementia. Existing studies have shown that aMCI is more likely to progress to AD than nonamnestic MCI. 19, 25 Moreover, the rate of pathologic AD at autopsy in a subset of the nonamnestic dysexecutive MCI participants in the NACC (36.3%) trended lower compared with a subset of the amnestic single-domain MCI participants (60.9%).
The dysexecutive and amnestic subgroups characterized in the current study did not differ in odds of having a pathologic diagnosis of AD. Although not significantly different, the AD dysexecutive subgroup had pathologic AD in >80% of participants as compared with 60% of the amnestic subgroup, the latter of which also captured several individuals with hippocampal sclerosis. These findings, and the fact that the amnestic subgroup accounted for only 27% of the current study sample, highlight the frequency of executive dysfunction in early AD. 26 Thus, the amnestic subgroup in the current study should not be considered typical AD, but rather a focal presentation used to create a clear distinction from the predominantly dysexecutive subgroup. A large portion of individuals in our study did not meet criteria for either of these "extreme" subgroups, and these individuals generally had demographic, genetic, and vascular characteristics that were intermediate between the amnestic and dysexecutive subgroup characteristics. Although subgroup categorization was based on only 2 neuropsychological tests, the construction of the subgroups is nonetheless meaningful: investigators have previously shown in ADNI that these subgroups, derived from very similar methodology, are biologically different, with the dysexecutive subgroup exhibiting greater frontoparietal cortical thinning on magnetic resonance imaging than the amnestic subgroup. 6 Further, composite scores for recently derived NACC neuropsychological factors 22 differed in the 2 subgroups. Expectedly, the subgroups differ in the executive and memory factors. Given the fact that the language factor is derived largely from the tests of semantic fluency (that tend to be impaired in conjunction with memory secondary to compromise of the medial temporal lobe), it is not surprising that the AD amnestic subgroup was also more impaired on this factor. No differences were seen on the attention factor. These results support the definition of amnestic versus dysexecutive subgroups implemented in the current study, as well as the existence of different subgroups within AD more broadly.
After controlling for covariates, the African Americans had greater odds of being members of the dysexecutive subgroup in MCI; however, ethnicity did not differ between the subgroups in mild AD. Healthy African American elders obtain lower scores on tests of executive function compared with whites. 27 Perhaps, the finding in MCI reflects these differences in specificity of executive function measures among cognitively normal African Americans rather than a finding specific to AD pathology. Future longitudinal analyses would help clarify whether the African Americans in the dysexecutive subgroup might develop AD at a lower rate compared with the African Americans in the amnestic subgroup, as these data may intimate.
After controlling for covariates, the dysexecutive subgroup was older than the amnestic subgroup in MCI but was younger than the amnestic subgroup in mild AD. The dysexecutive subgroup also had fewer years of education compared with the amnestic subgroup in MCI, but years of education did not differ between the subgroups in mild AD. Advanced age and fewer years of education are associated with lower scores on tests of executive function in healthy elders. 28 Perhaps the age and education findings in MCI reflect these differences among cognitively normal elders rather than a finding specific to AD pathology. Age of onset for focal, nonamnestic presentations of AD has been reported to be earlier compared with typical presentations of AD. 29 The younger age of the dysexecutive subgroup in AD might echo these findings in the literature. Future longitudinal analyses would also help clarify whether an older or less educated subset of the dysexecutive subgroup might develop AD at a lower rate compared with the amnestic subgroup as these data may intimate.
We decided to look at APOEe4 frequency in the amnestic and dysexecutive subgroups because AD-APOEe4 carriers have been found to have greater memory deficits and greater medial temporal atrophy compared with noncarriers. 30, 31 In addition, AD noncarriers have been found to have greater executive impairment and greater frontoparietal atrophy compared with carriers. 31, 32 In our study, after controlling for covariates, under an additive genetic model, participants with the APOEe4 allele had smaller odds of membership in the dysexecutive subgroup compared with the amnestic subgroup. These findings were still present when stratified into MCI and mild AD. This result replicates data from ADNI 6 in a considerably larger sample using a superior genetic model. Unlike previous studies, our additive model controls for potential effect modulators and demonstrates a dose-effect on the basis of the number of APOEe4 alleles.
In the NACC sample used for this study, there were 1861 whites (83.7%) and 219 African Americans (9.8%). Given that whites make up most of the sample, it is not surprising that the results of the full-sample APOE analysis were replicated in the whites when analyses were stratified by race. When we performed this analysis in the African Americans, there was no significant difference in the odds of individuals with the APOEe4 allele in each subgroup. Nonetheless, the OR in African Americans was similar to the OR in whites. Given the small number of African Americans, our study might lack the power to detect a true difference. Alternatively, this might reflect the historically weaker APOEe4-AD association in African Americans. 24 After controlling for covariates, participants in the dysexecutive subgroup had a smaller odds of having a history of hypertension compared with the participants in the amnestic subgroup. The 2 subgroups did not differ in odds of history of hyperlipidemia, diabetes, stroke, or MI. When a vascular score was calculated on the basis of the number of vascular risk factors, the 2 subgroups did not differ after controlling for covariates. These findings suggest that the dysexecutive subgroup is not associated with increased vascular risk factors either individually or additively compared with the amnestic subgroup. Multiple studies suggest that AD patients with vascular risk factors have more executive impairment compared with those without vascular risk factors. 16, 17 Multiple studies also suggest that AD patients with vascular risk factors including hypertension have more memory impairment compared with those without vascular risk factors. 16, 33 Although it may be a widely held belief that an increase in vascular risk factors leads to relatively more executive dysfunction compared with memory dysfunction in AD, the literature does not address this question directly. Our findings suggest that the vascular risk factors do not impose a disproportionate executive to memory burden in AD, and in fact hypertension may impose a disproportionate memory to executive burden in AD. Our findings might also suggest that executive dysfunction might have another underlying etiology besides subcortical white matter disease such as increase in plaque and tangle pathology in the prefrontal cortex.
The study has several limitations. Participant demographics and clinical criteria may have lacked uniformity, given the heterogeneity of the 29 ADCs contributing to the NACC database. Nonetheless, the large NACC sample size should have reduced the likelihood that false positives contaminated the results. Further, the heterogeneity allows for greater generalizability to other populations.
Another limitation is the limited utility of trails B in individuals with poor education or who lack familiarity with the English alphabet. Although one may argue that our findings in African Americans may be disproportionately affected by this limitation, we control for education in our model.
Within MCI, the requirement that all participants have memory impairment might suggest that the dysexecutive subgroup (that must be multidomain MCI) had more advanced disease compared with the amnestic subgroup (that could be either single-domain or multidomain MCI), confounding the comparison. However, it was not the case that both groups had comparable memory loss, with additional executive dysfunction in the dysexecutive group. Rather, memory was more impaired in the amnestic subgroup than in the dysexecutive subgroup, suggesting that the 2 groups were qualitatively different presentations rather than similar presentations at different points on a continuum. Further, to be sure that disease severity did not drive the current results, we controlled for global cognition in our regression analyses.
This study illustrates the distinct demographic, genetic, and vascular characteristics of a dysexecutive subgroup of AD. Specifically, it further supports data indicating that APOE impacts the clinical presentation of AD through effects on the anatomic distribution of the disease. 31 Future studies should investigate additional non-APOE-mediated susceptibility factors that participate in executive dysfunction in AD and potential differences in rate of decline across the various AD subgroups. Well-defined AD clinical phenotypes likely will have value in differential diagnosis and prognostication in clinical practice and in uniform patient recruitment for genetic studies and clinical trials.
